Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective-Reference-Cited by-同舟云学术

Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective

Published:2021-03 Issue:3 Volume:39 Page:394-406.e4
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Ramelyte Egle^ORCID,Tastanova Aizhan^ORCID,Balázs Zsolt,Ignatova Desislava,Turko Patrick^ORCID,Menzel Ulrike,Guenova Emmanuella,Beisel Christian,Krauthammer Michael^ORCID,Levesque Mitchell Paul,Dummer Reinhard

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference71 articles.

1. Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity;Ager;Cancer Immunol. Res.,2017

2. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma;Andtbacka;J. Clin. Oncol.,2015

3. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial;Andtbacka;Ann. Surg. Oncol.,2016

4. HVEM and nectin-1 are the major mediators of herpes simplex virus 1 (HSV-1) entry into human conjunctival epithelium;Akhtar;Invest Ophthalmol Vis Sci,2008

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Progress of Oncolytic Virus;Journal of Biomedical Nanotechnology;2024-10-01

3. oHSV2-mGM repolarizes TAMs and cooperates with αPD1 to reprogram the immune microenvironment of residual cancer after radiofrequency ablation;Biomedicine & Pharmacotherapy;2024-09

4. Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy;Clinical and Experimental Medicine;2024-08-28

5. Safety of non-replicative and oncolytic replication-selective HSV vectors;Trends in Molecular Medicine;2024-08